Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Praxis Precision Medicines ( (PRAX) ).
On October 16, 2025, Praxis Precision Medicines announced positive topline results from its Phase 3 Essential3 program for ulixacaltamide, aimed at treating essential tremor. The studies demonstrated statistically significant improvements in patients’ conditions, with ulixacaltamide showing a 4.3-point mean improvement in mADL11 scores compared to placebo. The drug was generally well tolerated, with no drug-related serious adverse events reported. These results position Praxis favorably within the neurological treatment market and potentially offer a new therapeutic option for essential tremor, pending regulatory approval.
The most recent analyst rating on (PRAX) stock is a Buy with a $270.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines’ overall stock score is primarily impacted by its challenging financial performance, characterized by significant net losses and negative cash flows. While the earnings call provided positive insights into clinical advancements and a strong cash position, these are overshadowed by the company’s operational inefficiencies and valuation concerns. The technical analysis suggests a neutral trend, offering little support to the stock’s attractiveness.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines, Inc. operates in the pharmaceutical industry, focusing on developing treatments for neurological disorders. The company’s primary product in development is ulixacaltamide, which targets essential tremor, a condition affecting an estimated 7 million people in the U.S.
Average Trading Volume: 466,128
Technical Sentiment Signal: Hold
Current Market Cap: $1.21B
For detailed information about PRAX stock, go to TipRanks’ Stock Analysis page.